Tag Archives: Caprelsa® (vandetanib)

Sanofi’s subsidiary Genzyme to acquire Caprelsa® (vandetanib) from AstraZeneca

Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa®(vandetanib) from AstraZeneca Paris, France,  30-7-2015 — /EuropaWire/ — Sanofi and its subsidiary Genzyme announced today that it has entered into a definitive agreement with AstraZeneca to acquire Caprelsa® (vandetanib), a … Read the full press release